Skadden is representing Cephalon, Inc. in its $6.8 billion acquisition by Teva Pharmaceutical Industries Ltd., announced May 2. Cephalon is a global biopharmaceutical company.
Skadden is representing Cephalon, Inc. in its $6.8 billion acquisition by Teva Pharmaceutical Industries Ltd., announced May 2. Cephalon is a global biopharmaceutical company.